[HTML][HTML] The global burden of metabolic disease: Data from 2000 to 2019

NWS Chew, CH Ng, DJH Tan, G Kong, C Lin, YH Chin… - Cell Metabolism, 2023 - cell.com
Global estimates of prevalence, deaths, and disability-adjusted life years (DALYs) from the
Global Burden of Diseases, Injuries, and Risk Factors Study 2019 were examined for …

Unveiling the cancer risk nexus of the steatotic liver

J Kim, E Seki - Trends in Endocrinology & Metabolism, 2024 - cell.com
Steatotic liver, characterized by the accumulation of fat in the liver, poses significant health
risks including metabolic dysfunction-associated steatotic liver disease (MASLD) and an …

[HTML][HTML] Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

MH Le, DM Le, TC Baez, H Dang… - Clinical and …, 2024 - ncbi.nlm.nih.gov
Methods We performed a systematic review and meta-analysis of cohort studies of adults
with NAFLD to evaluate the pooled incidence of adverse events. Results 19,406 articles …

Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction

YH Chin, J Lim, G Kong, CH Ng, R Goh… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To examine the prevalence and prognosis of hepatic steatosis and fibrosis in post‐
acute myocardial infarction (AMI) patients. Methods Patients presenting with AMI to a tertiary …

The prognostic value of including non‐alcoholic fatty liver disease in the definition of metabolic syndrome

CE Fu, JN Yong, CH Ng, B Nah… - Alimentary …, 2023 - Wiley Online Library
Summary Background/Aims Metabolic syndrome (MetS) affects over one third of the US
adult population. Despite its close association with non‐alcoholic fatty liver disease …

Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies

JH Hong, CH Yong, HL Heng, JY Chan, MC Lau… - Gut, 2024 - gut.bmj.com
Objectives Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality
and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA …

the heart of NAFLD

NWS Chew, S Kannan, B Chong, Y Chin… - Frontiers in …, 2023 - frontiersin.org
The silent obesity epidemic has led to the rising global prevalence of non-alcoholic fatty liver
disease (NAFLD). This metabolic burden is a growing public health concern as forecast …

[HTML][HTML] EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

F Tacke, P Horn, VWS Wong, V Ratziu, E Bugianesi… - Journal of …, 2024 - Elsevier
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Relationship between non-alcoholic fatty liver disease and visceral fat measured by imaging-based body composition analysis: a systematic review

KM Seaw, CJ Henry, X Bi - Livers, 2023 - mdpi.com
Imaging-based body composition analysis can quantify visceral fat, which is an important
feature of lean non-alcoholic fatty liver disease (NAFLD) patients. This review assesses …

Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation

MS Siddiqui, M Muthiah, SK Satapathy, K Patidar… - Hepatology, 2023 - journals.lww.com
Occurrence of metabolic dysfunction associated steatotic liver (MASLD) is common following
liver transplantation (LT). MASLD can be classified as recurrent disease when it occurs in …